Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: A randomized, open-label, multicenter study in Greece

Journal of Glaucoma

Volumn 10, Issue 4, 2001, Pages 316-324

  Petounis, Andreas ^a   Mylopoulos, Nikolaos ^b   Kandarakis, Artemios ^c   Andreanos, Dimitrios ^a   Dimitrakoulias, Nikolaos ^d  

^a IASO GENERAL HOSPITAL   (Greece)

^b Ippokration Hospital Thessaloniki   (Greece)

^c Polykliniki Hospital   (Greece)

^d AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Dorzolamide; Glaucoma; Intraocular pressure; Latanoprost; Timolol

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DORZOLAMIDE; LATANOPROST; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INSTILLATION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GREECE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRESSURE MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 0034865404     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/00061198-200108000-00012     Document Type: Article

References (37)

1. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open angle glaucoma
2. Long term evaluation of timolol
3. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma
4. Serial administration of adrenergic antagonist and agonist (pulsatile therapy) reduces the incidence of long-term drift to humans
5. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans
6. Four week safety and efficacy study of dorzolamide, a novel active topical carbonic anhydrase inhibitor
7. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure
8. A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension
9. The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension
10. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomized study
11. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor
12. Latanoprost: Two year experience of its use in the United Kingdom
13. Latanoprost, a prostaglandin analogue, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients
14. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States
15. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol
16. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States
17. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: A 12 week study
18. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol
19. Additive effect of latanoprost, a prostaglandin F2a analogue, and timolol in patients with elevated intraocular pressure
20. The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents
21. Intraocular pressure lowering effect of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: A randomized, observer-masked multicenter study in patients with open angle glaucoma
22. Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure
23. 2α isopropylester to timolol in patients with open angle glaucoma: A randomised, masked, placebo-controlled study
24. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow
25. Compliance with medical treatment of glaucoma
26. Comparison of glaucomatous progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressure
27. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: A 3-month, randomized study
28. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma
29. Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects
30. Aqueous humor dynamics in the aging human eye
31. Histopathologic study of conjunctiva after long-term latanoprost (Xalatan) treatment
32. Effects on intraocular pressure restoration and blood aqueous barrier after long-term treatment with latanoprost in POAG and ocular hypertension
33. Anterior uveitis associated with latanoprost
34. Irreversible corneal decompensation in patients treated with topical dorzolamide
35. Corneal endothelial involvement in pseudoexfoliation syndrome
36. Keratopathy in pseudoexfoliation syndrome as a cause of corneal endothelial decompensation. A clinicopathologic study